ISRG Stock Sinks as Analysts Cut Price Targets on Intuitive Surgical
ISRG Stock Sinks as Analysts Cut Price Targets on Intuitive Surgical.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Intuitive Surgical (ISRG) is under immense pressure on Friday as muted full-year guidance triggered a wave of Wall Street price cuts.
Despite beating Q2 earnings estimates, ISRG's relative strength index (RSI) crashed into the early 30s, indicating the stock is now approaching oversold territory that often triggers a relief rally.
Micron Stock Is Off 31% From Its High. Why This Could Be the Best Time to Buy.
Michael Saylor's Bitcoin Treasury Company Strategy Is Falling Apart
This Red-Hot AI Infrastructure Stock Just Made a Game-Changing Move. How to Play NBIS Here.
Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now!
Following the post-earnings decline, Intuitive Surgical stock is down roughly 40% versus its year-to-date high.
ISRG stock is being sold off mostly because of the expected deceleration in U.S. procedure growth.
In its earnings release, management said da Vinci procedure growth is now expected to track closer to 14.5% this year, the exact midpoint of its previously guided range.
This minor downward adjustment overshadowed an otherwise healthy quarter where worldwide procedures grew 16% on a year-over-year basis.
Investors are particularly concerned that changes to Affordable Care Act exchange coverage could weigh on elective procedure volumes.
These regulatory shifts have forced Intuitive Surgical into a conservative posture, signaling a potential moderation in procedure-driven instrument demand over the near term.
ISRG's cautious outlook sparked a cascade of valuation downgrades across major banking firms.
Citi adjusted its near-term expectations by lowering the price target to $500, while maintaining a "Buy" rating, concurrently removing its 90-day upside catalyst watch due to rising healthcare policy headwinds.
JPMorgan enacted a similar reduction, cutting its price target to $450. Its analysts noted that despite robust quarterly profitability and steady system placements, the "flatter" procedure trajectory will act as a ceiling on the stock.
Mizuho lowered its price objective as well, to $400, sticking to a "Hold" rating as demand for auxiliary components begins to stall.
Bernstein proved to be the most optimistic, yet still slashed its price target from $750 to $685 while keeping an "Outperform" rating, warning that debate surrounding U.S. procedure growth may depress multiples in the current quarter.
